Supporting great science from around the world
The Powered by CARB-X portfolio is the world’s largest and most diverse portfolio of antibacterial projects. CARB-X supports projects through the early development phases and Phase 1 clinical trials so that they will attract additional private or public support for further clinical development. CARB-X projects are selected through a global competitive process. To be considered, projects must target resistant bacteria on the Serious or Urgent Threat List issued by the CDC or on the Priority Pathogens list published by the WHO. Applications are vetted by the CARB-X Advisory Board and final funding decisions are made by the CARB-X Joint Oversight Committee.
CARB-X provides non-dilutive funding to partner companies to support the early development of antibiotics, rapid diagnostics, vaccines and other life-saving products. The portfolio is constantly evolving, with new projects, advancements into clinical development, and achievement of milestones on the path to clinical trials.